Overcoming obstacles to enable access to medicines for noncommunicable diseases in poor countries

Health Affairs

Volumn 34, Issue 9, 2015, Pages 1569-1577

  Kishore, Sandeep P ^a,b   Kolappa, Kavitha ^b,c   Jarvis, Jordan D ^b   Park, Paul H ^d   Belt, Rachel ^d   Balasubramaniam, Thirukumaran ^e   Kiddell Monroe, Rachel ^f  

^a YALE UNIVERSITY   (United States)

^b Young Professionals Chronic Disease Network   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Universities Allied for Essential Medicines   (United States)

^e Knowledge Ecology International   (Switzerland)

^f MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; BIOSIMILAR AGENT; DASATINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METHOTREXATE; PACLITAXEL; SORAFENIB; TAMOXIFEN; TRASTUZUMAB; ESSENTIAL DRUG;

ACCESS TO MEDICINE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS PATIENT; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; DRUG INDUSTRY; ECONOMIC DEVELOPMENT; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; MEDICINE; NON COMMUNICABLE DISEASE; ORGANIZATION AND MANAGEMENT; PATENT; PRESCRIPTION; SOCIETY; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; CHRONIC DISEASE; COMMUNICABLE DISEASES; DEVELOPING COUNTRY; DRUG COST; ECONOMICS; FEMALE; GLOBAL HEALTH; HEALTH CARE COST; HEALTH CARE DELIVERY; MALE; MANAGEMENT; POVERTY; PRACTICE GUIDELINE; PRIVATE SECTOR; PUBLIC SECTOR; SOCIOECONOMICS;

CHRONIC DISEASE; COMMUNICABLE DISEASES; DEVELOPING COUNTRIES; DRUG COSTS; DRUG INDUSTRY; DRUGS, ESSENTIAL; FEMALE; GLOBAL HEALTH; GUIDELINES AS TOPIC; HEALTH CARE COSTS; HEALTH CARE REFORM; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; POLICY MAKING; POVERTY; PRIVATE SECTOR; PUBLIC SECTOR; SOCIOECONOMIC FACTORS;

EID: 84942328104     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2015.0375     Document Type: Article

References (46)

1. Quick JD, Hogerzeil HV, Velasquez G, Rago L. Twenty-five years of essential medicines. Bull World Health Organ. 2002;80(11): 913-4.
2. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373(9659): 240-9.
3. Hanna TP, Kangolle AC. Cancer control in developing countries: using health data and health services research to measure and improve access, quality, and efficiency. BMC Int Health Hum Rights. 2010; 10: 24.
4. Thakur J, Prinja S, Garg CC, Mendis S, Menabde N. Social and economic implications of noncommunicable diseases in India. Indian J Community Med. 2011;36(Suppl 1):S13-22.
5. World Health Organization. Global strategy for the prevention and control of noncommunicable diseases [Internet]. Geneva: WHO; 2000 Mar 22 [cited 2015 Aug 5]. Available from: http://apps.who.int/gb/archive/pdf_files/WHA53/ea14.pdf
6. World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013-2020 [Internet]. Geneva: WHO; 2013 [cited 2015 Aug 5]. Available from: http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf?ua=1
7. United Nations General Assembly. Political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases [Internet]. New York (NY): UN; 2011 Sep 19 [cited 2015 Aug 5]. Available from: http://www.who.int/nmh/events/un_ncd_summit2011/political_declaration_en.pdf
8. Kishore SP, Vedanthan R, Fuster V. Promoting global cardiovascular health ensuring access to essential cardiovascular medicines in low- and middle-income countries. J Am Coll Cardiol. 2011;57(20): 1980-7.
9. Abegunde D. Essential medicines for non-communicable diseases (NCDs) [Internet]. Geneva: World Health Organization; 2011 [cited 2015 Aug 5]. Available from: http://www.who.int/medicines/areas/policy/access_noncommunicable/EssentialMedicinesforNCDs.pdf
10. USA.gov. The United States President's Emergency Plan for AIDS Relief [home page on the Internet]. Washington (DC): PEPFAR; [cited 2015 Aug 5]. Available from: http://www.pepfar.gov
11. Stop TB Partnership [home page on the Internet]. Geneva: Stop TB Partnership; [cited 2015 Aug 5]. Available from: http://www.stoptb.org
12. Billo NE. Asthma Drug Facility, GARD meeting [Internet]. Paris (France): International Union against Tuberculosis and Lung Disease; 2007 Jun [cited 2015 Aug 5]. Available from: http://www.who.int/gard/news_events/5-6Asthma%20Drug%20Facility-Dr%20N.billo.pdf
13. Pan American Health Organization. Strategic fund [Internet]. Washington (DC): PAHO; [cited 2015 Aug 5]. Available from: http://www.paho.org/hq/index.php?option=com_content&view=category&layout=blog&id=1159&Itemid=452
14. Beran D, Perrin C, Billo N, Yudkin JS. Improving global access to medicines for non-communicable diseases. Lancet Glob Health. 2014; 2(10): e561-2.
15. United Nations. "Can we and should we not do better", panellist asks General Assembly as it concludes high-level meeting on non-communicable diseases [Internet]. New York (NY): UN; 2014 Jul 11 [cited 2015 Aug 5]. Available from: http://www.un.org/press/en/2014/ga11532.doc.htm
16. Kishore SP, Herbstman BJ. Adding a medicine to the WHO model list of essential medicines. Clin Pharmacol Ther. 2009;85(3): 237-9.
17. To access the Appendix, click on the Appendix link in the box to the right of the article online.
18. Hoen E, Berger J, Calmy A, Moon S. Driving a decade of change: HIV/AIDS, patents, and access to medicines for all. J Int AIDS Soc. 2011; 14:15.
19. Medindia. Drug information on Sprycelfi[tab] (dasatinib) from Bristol [Internet]. Chennai: Med-india; [cited 2015 Aug 5]. Available from: http://www.medindia.net/drug-price/dasatinib/sprycel-tab.htm
20. Kishore SP, Kolappa K. Unlikely allies. Huffington Post [blog on the Internet]. 2014 Feb 14 [cited 2015 Aug 5]. Available from: http://www.huffingtonpost.com/sandeep-p-kishore-phd/healthy-living-news_b_4781300.html
21. Creese A. WHO/HAI project on medicine prices and availability: review series on pharmaceutical pricing policies and interventions: sales taxes on medicines [Internet]. Geneva: World Health Organization; 2011 May [cited 2015 Aug 5]. (Working Paper No. 5). Available from: http://www.haiweb.org/medicineprices/05062011/TaxesfinalMay2011.pdf
22. Open Society Foundations. Stop stock-outs campaign [Internet]. New York (NY): Open Society Foundations; [cited 2015 Aug 5]. Available from: http://stopstockouts.org/stop-stock-outs-campaign/
23. International Federation of Pharmaceutical Manufacturers and Associations. IFPMA framework for action on NCDs 2011-2012 progress report [Internet]. Geneva: IFPMA; 2011 Jun [cited 2015 Aug 5]. Available from: http://www.ifpma.org/fileadmin/content/Publication/2012/IFPMA_Framework_for_action_on_NCDs_WEB.pdf
24. Knowledge Ecology International, University of California, San Francisco, Universities Allied for Essential Medicines. Proposal for the inclusion of trastuzumab in the WHO model list of essential medicines for the treatment of HER2-positive breast cancer [Internet]. Washington (DC): Knowledge Ecology International; 2012 Nov 30 [cited 2015 Aug 5]. Available from: http://www.who.int/selection_medicines/committees/expert/19/applications/Trastuzumab2_8_2_A_Ad.pdf
25. Gokhale K. Merck to Bristol-Myers face more threats on India patents. Bloomberg News [serial on the Internet]. 2014 Jan 28 [cited 2015 Aug 5]. Available from: http://www.bloomberg.com/news/articles/2014-01-21/merck-to-bristol-myers-face-more-threats-on-india-patents
26. Collier R. Drug patents: the ever-greening problem. CMAJ. 2013; 185(9): E385-6.
27. Love J. Senator Sanders Amendment 2858 would replace data exclusivity with cost sharing, if new trials violate medical ethics. Knowledge Ecology International [blog post on the Internet]. 2009 Dec 4 [cited 2015 Aug 5]. Available from: http://keionline.org/node/707
28. United Nations Conference on Trade and Development. Using intellectual property rights to stimulate pharmaceutical production in developing countries: a reference guide [Internet]. New York (NY): UN; 2011 [cited 2015 Aug 5]. Available from: http://unctad.org/es/Docs/diaepcb2009d19_en.pdf
29. European Commission. Trade agreement between the European Union and its member states, of the one part, and Colombia and Peru, of the other part [Internet]. Brussels: European Union; 2011 [cited 2015 Aug 5]. Available from: http://trade.ec.europa.eu/doclib/docs/2011/march/tradoc_147704.pdf
30. Chan M. WHO Director-General addresses ministerial meeting on universal health coverage [Internet]. Geneva: World Health Organization; 2015 Feb 10 [cited 2015 Aug 5]. Available from: http://www.who.int/dg/speeches/2015/singapore-uhc/en/
31. Tufts Center for the Study of Drug Development. Cost to develop and win marketing approval for a new drug is $2.6 billion [Internet]. Boston (MA): The Center; 2014 Nov 18 [cited 2015 Aug 5]. Available from: http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study
32. Mestre-Ferrandiz J, Sussex J, Towse A. The R&D cost of a new medicine [Internet]. London (UK): Office of Health Economics; 2012 Dec [cited 2015 Aug 5]. Available from: http://www.ohe.org/publications/rd-cost-new-medicine
33. Drugs for Neglected Diseases Initiative. An innovative approach to R&D for neglected patients. Ten years of experience and lessons learned by DNDi [Internet]. Geneva: DNDi; 2014 Jan [cited 2015 Aug 5]. Available from: http://www.dndi.org/images/stories/pdf_aboutDNDi/DNDiModel/DNDi_Modelpaper_2013.pdf
34. 't Hoen E. Access to cancer treatment: a study of medicine pricing issues with recommendations for improving access to cancer medication [Internet]. Oxford: Oxfam; 2015 Feb [cited 2015 Aug 5]. Available from: http://apps.who.int/medicinedocs/documents/s21758en/s21758en.pdf
35. de Cates AN, Farr MR, Wright N, Jarvis MC, Rees K, Ebrahim S, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014; 4: CD009868.
36. Huffman MD, de Cates AN, Ebrahim S. Fixed-dose combination therapy (polypill) for the prevention of cardiovascular disease. JAMA. 2014; 312(19): 2030-1.
37. World Health Organization. The global strategy and plan of action on public health, innovation, and intellectual property [Internet]. Geneva: WHO; [cited 2015 Aug 5]. Available from: http://www.who.int/phi/implementation/phi_globstat_action/en/
38. World Intellectual Property Organization. Committee on Development and Intellectual Property, fourteenth session [Internet]. Geneva: WIPO; 2014 Sep 19 [cited 2015 Aug 5]. Available from: http://www.wipo.int/edocs/mdocs/mdocs/en/cdip_14/cdip_14_inf_12.pdf
39. iCancer. People before profit. Let's crowdfund the anti-cancer virus that could save thousands [home page on the Internet]. [Location unknown]: iCancer; [cited 2015 Aug 5]. Available from: http://icancer.org.uk
40. Longitude Prize. Antibiotics [Internet]. London: Nesta; [cited 2015 Aug 5]. Available from: https://longitudeprize.org/challenge/antibiotics
41. Knowledge Ecology International. Standard template for a candidate demonstration project [Internet]. Washington (DC): KEI; [cited 2015 Aug 5]. Available from: http://keionline.org/sites/default/files/OpenSourceCancerDiagnosticsPAHO3Sep2013.pdf
42. Hogerzeil HV, Liberman J, Wirtz VJ, Kishore SP, Selvaraj S, Kiddell-Monroe R, et al. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. Lancet. 2013;381(9867): 680-9.
43. Siegel KR, Feigl AB, Kishore SP, Stuckler D. Misalignment between perceptions and actual global burden of disease: evidence from the US population. Glob Health Action. 2011;4.
44. Motsoeneng T. South Africa slams big pharma in generic drug row. Reuters [serial on the Internet]. 2014 Jan 27 [cited 2015 Aug 5]. Available from: http://www.reuters.com/article/2014/01/17/us-safrica-pharma-idUSBREA0G0N720140117
45. Cohen D. Will industry influence derail UN summit? BMJ. 2011;343: d5328.
46. Civil Society in Development. The Civil Society Fund-funding for Danish CSOs [Internet]. Aarhus C (Denmark): CISU; [cited 2015 Aug 5]. Available from: http://www.cisu.dk/the-civil-society-fund/overview